Mitochondria–A target for attenuation of astrocyte pathology

Marlene Thorsen Morch, Reza Khorooshi, Joanna Marczynska, Magdalena Dubik, Soeren Nielsen, John Dirk Nieland, Nasrin Asgari, Trevor Owens*

*Corresponding author for this work

Research output: Contribution to journalJournal articleResearchpeer-review

29 Downloads (Pure)


Astrocyte pathology is a feature of neuromyelitis optica spectrum disorder (NMOSD) pathology. Recently mitochondrial dysfunction and metabolic changes were suggested to play a role in NMOSD. To elucidate the role of mitochondrial dysfunction, astrocyte pathology was induced in C57BL/6 J female mice by intracerebral injection of aquaporin-4-immunoglobulin G from an NMOSD patient, together with complement. Etomoxir has been shown to cause mitochondrial dysfunction. Etomoxir was delivered to the central nervous system and resulted in decreased astrocyte pathology. The ameliorating effect was associated with increases in different acylcarnitines and amino acids. This suggests that mitochondria may be a therapeutic target in NMOSD.

Original languageEnglish
Article number577657
JournalJournal of Neuroimmunology
Number of pages5
Publication statusPublished - 15. Sept 2021

Bibliographical note

Publisher Copyright:
© 2021 The Authors


  • Astrocyte pathology
  • Central nervous system
  • Etomoxir
  • Metabolic
  • Mitochondrial dysfunction
  • Neuromyelitis optica spectrum disorder


Dive into the research topics of 'Mitochondria–A target for attenuation of astrocyte pathology'. Together they form a unique fingerprint.

Cite this